Atea Pharmaceuticals, Inc. Research and Development Expense
Atea Pharmaceuticals, Inc. (AVIR) reported Research and Development Expense of $28.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $28.15M, a 12.78% decline year-over-year.
- Atea Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $41.13M, a 39.04% increase year-over-year.
- Atea Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $47.82M, a 86.27% increase year-over-year.
- Atea Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $38.35M, a 46.59% increase year-over-year.
- Atea Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $148.02M, a 2.72% increase from fiscal 2024.
- Atea Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $144.10M, a 26.14% increase from fiscal 2023.
- Atea Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $114.24M, a 39.43% increase from fiscal 2022.
- Atea Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $81.94M, a 51.00% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.15M 10-Q · filed 2026-08-12 | $69.28M 10-Q · filed 2026-08-12 | $117.10M derived: sum of 3 quarters · filed 2026-08-12 | $155.45M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $41.13M 10-Q · filed 2026-05-12 | $88.95M derived: sum of 2 quarters · filed 2026-05-12 | $127.30M derived: sum of 3 quarters · filed 2026-05-12 | $159.57M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $47.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $86.17M derived: sum of 2 quarters · filed 2026-03-05 | $118.44M derived: sum of 3 quarters · filed 2026-08-12 | $148.02M 10-K · filed 2026-03-05 |
| 2025-09-30 | $38.35M 10-Q · filed 2025-11-12 | $70.62M derived: sum of 2 quarters · filed 2026-08-12 | $100.21M 10-Q · filed 2025-11-12 | $125.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $32.27M 10-Q · filed 2026-08-12 | $61.86M 10-Q · filed 2026-08-12 | $87.53M derived: sum of 3 quarters · filed 2026-08-12 | $113.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $29.58M 10-Q · filed 2026-05-12 | $55.26M derived: sum of 2 quarters · filed 2026-05-12 | $81.41M derived: sum of 3 quarters · filed 2026-05-12 | $116.11M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $25.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $51.83M derived: sum of 2 quarters · filed 2026-03-05 | $86.53M derived: sum of 3 quarters · filed 2026-03-05 | $144.10M 10-K · filed 2026-03-05 |
| 2024-09-30 | $26.16M 10-Q · filed 2025-11-12 | $60.85M derived: sum of 2 quarters · filed 2025-11-12 | $118.43M 10-Q · filed 2025-11-12 | $153.47M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $34.70M 10-Q · filed 2025-08-07 | $92.27M 10-Q · filed 2025-08-07 | $127.32M derived: sum of 3 quarters · filed 2025-08-07 | $155.50M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $57.58M 10-Q · filed 2025-05-12 | $92.62M derived: sum of 2 quarters · filed 2025-05-12 | $120.80M derived: sum of 3 quarters · filed 2025-05-12 | $142.86M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $35.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $63.23M derived: sum of 2 quarters · filed 2025-03-06 | $85.29M derived: sum of 3 quarters · filed 2025-03-06 | $114.24M 10-K · filed 2025-03-06 |
| 2023-09-30 | $28.18M 10-Q · filed 2024-11-07 | $50.24M derived: sum of 2 quarters · filed 2024-11-07 | $79.20M 10-Q · filed 2024-11-07 | $106.74M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $22.06M 10-Q · filed 2024-08-07 | $51.02M 10-Q · filed 2024-08-07 | $78.56M derived: sum of 3 quarters · filed 2024-08-07 | $83.46M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $28.95M 10-Q · filed 2024-05-14 | $56.49M derived: sum of 2 quarters · filed 2024-05-14 | $61.40M derived: sum of 3 quarters · filed 2024-05-14 | $81.26M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $27.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $32.45M derived: sum of 2 quarters · filed 2024-02-28 | $52.30M derived: sum of 3 quarters · filed 2024-02-28 | $81.94M 10-K · filed 2024-02-28 |
| 2022-09-30 | $4.91M 10-Q · filed 2023-11-08 | $24.76M derived: sum of 2 quarters · filed 2023-11-08 | $54.40M 10-Q · filed 2023-11-08 | $112.21M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $19.86M 10-Q · filed 2023-08-08 | $49.49M 10-Q · filed 2023-08-08 | $107.30M derived: sum of 3 quarters · filed 2023-08-08 | $150.32M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $29.63M 10-Q · filed 2023-05-08 | $87.44M derived: sum of 2 quarters · filed 2023-05-08 | $130.46M derived: sum of 3 quarters · filed 2023-05-08 | $170.27M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $57.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $100.83M derived: sum of 2 quarters · filed 2023-02-28 | $140.63M derived: sum of 3 quarters · filed 2023-02-28 | $167.21M 10-K · filed 2023-02-28 |
| 2021-09-30 | $43.02M 10-Q · filed 2022-11-07 | $82.82M derived: sum of 2 quarters · filed 2022-11-07 | $109.39M 10-Q · filed 2022-11-07 | $123.24M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $39.80M 10-Q · filed 2022-08-08 | $66.38M 10-Q · filed 2022-08-08 | $80.22M derived: sum of 3 quarters · filed 2023-02-28 | $93.82M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $26.57M 10-Q · filed 2022-05-10 | $40.42M derived: sum of 2 quarters · filed 2023-02-28 | $54.02M derived: sum of 3 quarters · filed 2023-02-28 | $61.77M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $13.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $27.45M derived: sum of 2 quarters · filed 2023-02-28 | $35.20M derived: sum of 3 quarters · filed 2023-02-28 | $38.02M 10-K · filed 2023-02-28 |
| 2020-09-30 | $13.60M 10-Q · filed 2021-11-12 | $21.36M derived: sum of 2 quarters · filed 2021-11-12 | $24.18M 10-Q · filed 2021-11-12 | $27.67M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $7.75M 10-Q · filed 2021-08-12 | $10.58M 10-Q · filed 2021-08-12 | $14.06M derived: sum of 3 quarters · filed 2022-02-28 | $16.48M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $2.82M 10-Q · filed 2021-05-13 | $6.31M derived: sum of 2 quarters · filed 2022-02-28 | $8.72M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $5.90M derived: sum of 2 quarters · filed 2022-02-28 | $10.17M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $2.41M 10-Q · filed 2020-12-10 | $6.68M 10-Q · filed 2020-12-10 | ||
| 2018-12-31 | $6.67M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |